{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:33:09Z","timestamp":1763037189715,"version":"3.44.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.pharma.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T06:15:28Z","timestamp":1527142528000},"page":"273-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["M\u00e9canismes d\u2019action indirects et mixtes mis en jeu dans les myopathies toxiques"],"prefix":"10.1016","volume":"76","author":[{"given":"A.","family":"Khelfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Azzouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Abtroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Reggabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Alamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pharma.2018.03.004_bib0275","first-page":"1","article-title":"Syndrome s\u00e9rotoninergique\u00a0: une br\u00e8ve analyse","volume":"168","author":"Birmes","year":"2003","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.pharma.2018.03.004_bib0280","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5694\/j.1326-5377.2007.tb01282.x","article-title":"Serotonin toxicity: a practical approach to diagnosis and treatment","volume":"187","author":"Isbister","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.pharma.2018.03.004_bib0285","first-page":"164","article-title":"Syndrome malin des neuroleptiques et syndrome s\u00e9rotoninergique\u00a0: diagnostics positifs et diff\u00e9rentiels et \u00e9tiologies m\u00e9dicamenteuses","volume":"14","author":"Montastruc","year":"2000","journal-title":"Lett Pharmacol"},{"key":"10.1016\/j.pharma.2018.03.004_bib0290","first-page":"896","article-title":"Brain stem modulation of sensation, movement, and consciousness","volume":"4","author":"Saper","year":"2000","journal-title":"Princ Neural Sci"},{"issue":"5","key":"10.1016\/j.pharma.2018.03.004_bib0295","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00004714-199310000-00003","article-title":"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings","volume":"13","author":"Beasley","year":"1993","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.pharma.2018.03.004_bib0300","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1345\/aph.1L066","article-title":"Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome","volume":"42","author":"Stevens","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.pharma.2018.03.004_bib0305","first-page":"412","article-title":"Hyperthermie du syndrome malin des neuroleptiques, du syndrome s\u00e9rotoninergique, ou li\u00e9e \u00e0 l\u2019ecstasy\u00a0: approche th\u00e9rapeutique","volume":"10","author":"Hanna","year":"2001","journal-title":"Reanim"},{"issue":"3","key":"10.1016\/j.pharma.2018.03.004_bib0310","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/jnnp.58.3.271","article-title":"Neuroleptic malignant syndrome","volume":"58","author":"Buckley","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharma.2018.03.004_bib0315","unstructured":"Vidal. Paris ed; 2011."},{"issue":"3","key":"10.1016\/j.pharma.2018.03.004_bib0320","first-page":"5","article-title":"Mode d\u2019action des neurotoxines botuliques et t\u00e9tanique","volume":"157","author":"Popoff","year":"2004","journal-title":"Bull Acad Vet"},{"issue":"4","key":"10.1016\/j.pharma.2018.03.004_bib0325","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.toxicon.2006.11.016","article-title":"The differential preference of scorpion \u03b1-toxins for insect or mammalian sodium channels: implications for improved insect control","volume":"49","author":"Gordon","year":"2007","journal-title":"Toxicon"},{"issue":"5","key":"10.1016\/j.pharma.2018.03.004_bib0330","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/15563650701666306","article-title":"Clinical review of grayanotoxin\/mad honey poisoning past and present","volume":"46","author":"Gunduz","year":"2008","journal-title":"Clin Toxicol"},{"issue":"4","key":"10.1016\/j.pharma.2018.03.004_bib0335","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annfar.2008.02.010","article-title":"Neurotoxines ophidiennes","volume":"27","author":"Larr\u00e9ch\u00e9","year":"2008","journal-title":"Ann Fr Anesth Reanim"},{"issue":"3","key":"10.1016\/j.pharma.2018.03.004_bib0340","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/21678707.2014.887464","article-title":"3,4-Diaminopyridine (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome","volume":"2","author":"Lindquist","year":"2014","journal-title":"Expert Opin Orphan Drugs"},{"issue":"1","key":"10.1016\/j.pharma.2018.03.004_bib0345","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0041-0101(96)90057-4","article-title":"The kaliotoxin family: chemical, biological and genetic characterizations","volume":"34","author":"Martin-Euclaire","year":"1996","journal-title":"Toxicon"},{"issue":"5","key":"10.1016\/j.pharma.2018.03.004_bib0350","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.toxicon.2004.02.004","article-title":"Agatoxins: ion channel specific toxins from the American funnel web spider, Agelenopsis aperta","volume":"43","author":"Adams","year":"2004","journal-title":"Toxicon"},{"issue":"6","key":"10.1016\/j.pharma.2018.03.004_bib0355","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0196-0644(98)70076-9","article-title":"Envenomation by a spider, Agelenopsis aperta (Family: Agelenidae) previously considered harmless","volume":"32","author":"Vetter","year":"1998","journal-title":"Ann Emerg Med"},{"issue":"2","key":"10.1016\/j.pharma.2018.03.004_bib0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1530\/JOE-13-0504","article-title":"Antenatal corticosteroids alter insulin signaling pathways in fetal baboon skeletal muscle","volume":"221","author":"Blanco","year":"2014","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.pharma.2018.03.004_bib0365","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.pharma.2018.03.004_bib0370","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.pharma.2018.03.004_bib0375","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.pharma.2018.03.004_bib0380","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine"},{"issue":"19","key":"10.1016\/j.pharma.2018.03.004_bib0385","first-page":"887","article-title":"D-penicillamine and polymyositis - value of investigations for anti-Jo1\u00a0antibodies","volume":"15","author":"Oberlin","year":"1986","journal-title":"Presse Med"},{"issue":"8","key":"10.1016\/j.pharma.2018.03.004_bib0390","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1212\/WNL.28.8.847","article-title":"Penicillamine-induced myasthenia-gravis associated with antibodies to acetylcholine-receptor","volume":"28","author":"Russell","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.pharma.2018.03.004_bib0395","first-page":"1645","article-title":"Syndromes myasth\u00e9niques induits par la d-penicillamine au cours de la polyarthrite rhumato\u00efde-deux observations","volume":"10","author":"Rodat","year":"1981","journal-title":"Nouv Presse Med"},{"key":"10.1016\/j.pharma.2018.03.004_bib0400","first-page":"2336","article-title":"Myasth\u00e9nie induite par la d-p\u00e9nicillamine. \u00c9tude des corr\u00e9lations immuno-cliniques dans 23\u00a0cas","volume":"14","author":"d\u2019Angeljean","year":"1985","journal-title":"Presse Med"},{"key":"10.1016\/j.pharma.2018.03.004_bib0405","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0072-9752(07)86016-7","article-title":"Toxic and iatrogenic myopathies","volume":"86","author":"Mastaglia","year":"2007","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"10.1016\/j.pharma.2018.03.004_bib0410","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.45.2.382","article-title":"Myasthenia gravis during interferon alfa therapy","volume":"45","author":"Batocchi","year":"1995","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pharma.2018.03.004_bib0415","first-page":"75","article-title":"Development of myasthenia gravis after interferon alpha therapy","volume":"39","author":"Gurtubay","year":"1999","journal-title":"Electromyogr Clin Neurophysiol"},{"issue":"5\u20136","key":"10.1016\/j.pharma.2018.03.004_bib0420","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/0960-8966(94)90143-0","article-title":"Myasthenia gravis after interferon alpha therapy","volume":"4","author":"Palmisani","year":"1994","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.pharma.2018.03.004_bib0425","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0035-3787(07)92645-4","article-title":"Myofasciite \u00e0 macrophages\u00a0: \u00e9tat des connaissances","volume":"163","author":"Authier","year":"2007","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"10.1016\/j.pharma.2018.03.004_bib0430","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-014-3065-4","article-title":"Macrophagic myofasciitis and vaccination: consequence or coincidence?","volume":"35","author":"Santiago","year":"2015","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.pharma.2018.03.004_bib0435","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mehy.2008.09.040","article-title":"A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome","volume":"72","author":"Exley","year":"2009","journal-title":"Med Hypotheses"},{"issue":"1","key":"10.1016\/j.pharma.2018.03.004_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0388-2","article-title":"Fluorescent nanodiamonds as a relevant tag for the assessment of alum adjuvant particle biodisposition","volume":"13","author":"Eidi","year":"2015","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.pharma.2018.03.004_bib0445","first-page":"37","article-title":"Biopersistence and systemic distribution of intramuscularly injected particles: what impact on long-term tolerability of alum adjuvants?","volume":"198","author":"Gherardi","year":"2014","journal-title":"Bull Acad Natl Med"},{"issue":"12\u201313","key":"10.1016\/j.pharma.2018.03.004_bib0450","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0264-410X(97)00041-8","article-title":"In vivo absorption of aluminium-containing vaccine adjuvants using 26Al","volume":"15","author":"Flarend","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2018.03.004_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-11-99","article-title":"Slow CCL2-dependent translocation of biopersistent particles from muscle to brain","volume":"11","author":"Khan","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.pharma.2018.03.004_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2015.00004","article-title":"Biopersistance et translocation des adjuvants aluminiques des vaccins vers le cerveau","volume":"6","author":"Gherardi","year":"2015","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.pharma.2018.03.004_bib0465","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0735-1097(91)90794-A","article-title":"Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome","volume":"18","author":"Kilbourne","year":"1991","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharma.2018.03.004_bib0470","doi-asserted-by":"crossref","first-page":"140","DOI":"10.7326\/0003-4819-116-2-140","article-title":"The cause and pathogenesis of the eosinophilia-myalgia-syndrome","volume":"116","author":"Varga","year":"1992","journal-title":"Ann Intern Med"},{"issue":"45","key":"10.1016\/j.pharma.2018.03.004_bib0475","first-page":"765","article-title":"Eosinophilia-myalgia syndrome-New Mexico","volume":"38","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"13","key":"10.1016\/j.pharma.2018.03.004_bib0480","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM199003293221301","article-title":"Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan","volume":"322","author":"Hertzman","year":"1990","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharma.2018.03.004_bib0485","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0167-7799(94)90035-3","article-title":"Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale","volume":"12","author":"Mayeno","year":"1994","journal-title":"Trends Biotechnol"},{"issue":"11","key":"10.1016\/j.pharma.2018.03.004_bib0490","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00011-005-1380-7","article-title":"A heretofore undisclosed crux of Eosinophilia-Myalgia Syndrome: compromised histamine degradation","volume":"54","author":"Smith","year":"2005","journal-title":"Inflamm Res"},{"issue":"3","key":"10.1016\/j.pharma.2018.03.004_bib0495","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1248\/cpb.39.820","article-title":"Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography","volume":"39","author":"Toyo\u2019oka","year":"1991","journal-title":"Chem Pharm Bull"},{"issue":"4","key":"10.1016\/j.pharma.2018.03.004_bib0500","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bionut.2012.08.009","article-title":"Meta-analysis of electrolyte imbalance in human fluorosis","volume":"2","author":"Bhardwaj","year":"2012","journal-title":"Biomed Prev Nutr"},{"key":"10.1016\/j.pharma.2018.03.004_bib0505","series-title":"Trait\u00e9 de nutrition artificielle de l\u2019adulte","first-page":"323","article-title":"Muscle","author":"Couet","year":"2007"},{"issue":"1","key":"10.1016\/j.pharma.2018.03.004_bib0510","first-page":"46","article-title":"Intoxication au monoxyde de carbone","volume":"2","author":"Donati","year":"2005","journal-title":"EMC Anesth Reanim"},{"issue":"1","key":"10.1016\/j.pharma.2018.03.004_bib0515","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharma.2018.03.004_bib0520","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (<\u00a032\u00a0ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.pharma.2018.03.004_bib0525","series-title":"Diet and nutrition in dementia and cognitive decline","first-page":"167","article-title":"Chapter 16 - Wernicke\u2013Korsakoff syndrome and dementia","author":"Messina","year":"2015"},{"issue":"12","key":"10.1016\/j.pharma.2018.03.004_bib0530","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1111\/j.1742-4658.2008.06466.x","article-title":"Insights into and speculations about snake venom metalloproteinase (SVMP) synthesis, folding and disulfide bond formation and their contribution to venom complexity","volume":"275","author":"Fox","year":"2008","journal-title":"FEBS J"},{"issue":"11","key":"10.1016\/j.pharma.2018.03.004_bib0535","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.pmrj.2011.08.535","article-title":"Radiation fibrosis syndrome: neuromuscular and musculoskeletal complications in cancer survivors","volume":"3","author":"Stubblefield","year":"2011","journal-title":"PM&R"},{"key":"10.1016\/j.pharma.2018.03.004_bib0540","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.toxicon.2015.02.014","article-title":"Inflammation and oxidative stress in viper bite: an insight within and beyond","volume":"98","author":"Sunitha","year":"2015","journal-title":"Toxicon"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345091730041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345091730041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:33:43Z","timestamp":1757720023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000345091730041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S000345091730041X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2018.03.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M\u00e9canismes d\u2019action indirects et mixtes mis en jeu dans les myopathies toxiques","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}